DERM (Journey Medical) Other Financing: $-10.79 Mil (TTM As of Mar. 2026)


DERM Journey Medical Corp DERM
62 GF Score
Price $6.62
GF Value $4.17
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Journey Medical Other Financing?

Journey Medical DERM +6.43% 62 Other Financing is $-10.79 Mil as of Mar. 2026. GuruFocus rates DERM with a GF Score™ of 62/100 and a GF Value™ of $4.17 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Journey Medical's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Journey Medical's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.79 Mil.

Journey Medical Other Financing Historical Data

* Premium members only.

The historical data trend for Journey Medical's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Journey Medical Other Financing Chart

Journey Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -3.54 -0.44 -4.84 0.37 0.49

Journey Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.00 0.15 -10.93 0.00
DERM
62GF Score
Journey Medical Corp DERM
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Journey Medical Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-10.79 Mil mean?
Journey Medical (DERM) has a Other Financing of $-10.79 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Journey Medical and its competitors.
Is Journey Medical's Other Financing too high?
Journey Medical's current Other Financing is $-10.79 Mil. Overall, Journey Medical has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Other Financing compare to LFCR and ANIK?
Journey Medical's Other Financing of $-10.79 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Journey Medical and its competitors. Journey Medical's current Other Financing is $-10.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.17, compared to a current price of $6.62 — trading 58.8% above its estimated fair value. The current Other Financing is $-10.79 Mil. Journey Medical's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Journey Medical (DERM), the current Other Financing is $-10.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Journey Medical (DERM) Overvalued in 2026?

Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued. The current stock price of $6.62 is trading 58.8% above its estimated GF Value™ of $4.17. GuruFocus considers Journey Medical to be Significantly Overvalued.

Key valuation signals for DERM:

  • Other Financing: $-10.79 Mil
  • GF Value™: $4.17 vs. price of $6.62 (58.8% above fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Journey Medical Business Description

Address 9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
62GF Score

Get the complete analysis for DERM

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.62
Price
$4.17
GF Value